Q-omics provides the consensus-scored ZC3H10 profile across patient tissues and cancer cell-line models. ZC3H10 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, ZC3H10 is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, ZC3H10 RNA expression shows 21,101 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight SCLC, LIHC, and ACC as cancer lineages where ZC3H10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZC3H10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZC3H10 survival associations across molecular data types. ZC3H10 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZC3H10 RNA expression–survival associations across cancer types. High ZC3H10 expression shows unfavorable associations in KICH, ACC and LIHC, but favorable associations in SCLC, UCS and BRCA. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for ZC3H10 RNA expression.
This table summarizes ZC3H10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ZC3H10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZC3H10 shows lower tumor expression in THCA, KICH and UCEC and higher tumor expression in LIHC, HNSC and CHOL. The LIHC box plot shows higher ZC3H10 RNA expression in tumor versus normal tissue (log2 FC = +0.760, t-test p < 0.001).
This table shows molecular features associated with ZC3H10 in patient tissues and cancer cell lines. In patient samples, ZC3H10 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZC3H10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
